VYNE Therapeutics (VYNE) reports 20,000-share stock option award to director

Rhea-AI Filing Summary

VYNE Therapeutics Inc. reported that one of its non-employee directors received an annual stock option award on December 12, 2025, the date of the company’s annual meeting of stockholders. The option covers 20,000 shares of VYNE common stock with an exercise price of $0.3756 per share and a stated expiration date of December 11, 2035.

According to the filing, the option vests in full on December 12, 2026, provided the director continues to serve through that date. After this grant, the director beneficially owns 20,000 derivative securities directly, reflecting this stock option position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Little Elisabeth Sandoval

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

P.O. BOX 125

(Street)

STEWARTSVILLE NJ 08886

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.3756	12/12/2025		A		20,000		(1)	12/11/2035	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Represents the annual award to non-employee directors of the Issuer, awarded on the date of the Issuer's annual meeting of stockholders. The shares subject to the option vest on December 12, 2026, subject to the Reporting Person's continuous service through such date.

	/s/ Mutya Harsch, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VYNE (VYNE) disclose in this Form 4?

VYNE disclosed that a non-employee director received an annual stock option award for 20,000 shares of common stock on December 12, 2025.

What is the exercise price of the VYNE director’s stock options?

The stock option granted to the VYNE non-employee director has an exercise price of $0.3756 per share.

When do the VYNE director’s stock options vest and expire?

The options vest on December 12, 2026, subject to continuous service, and have an expiration date of December 11, 2035.

How many VYNE derivative securities does the director hold after this grant?

Following this grant, the director beneficially owns 20,000 derivative securities, representing the stock options reported in the filing.

What type of compensation does this VYNE Form 4 transaction represent?

The transaction represents the annual equity award to VYNE’s non-employee directors, delivered as a stock option grant tied to continued board service.

What security underlies the VYNE director’s stock options?

The options are exercisable for 20,000 shares of VYNE common stock, as specified in the filing’s derivative securities table.